Health Catalyst, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HCAT in the last 7 days.
STAAR Surgical appointed David Bailey, former CEO, as Chief Commercial Officer to lead EVO ICL business. Bailey previously grew international revenue to 74% and ICL revenue to $32 million. He will focus on expanding in Asia, South America, and Africa.
Kohl Simeon (Chief Executive Officer) purchased 59,000 shares of Health Catalyst, Inc. (HCAT) at $1.79 ($0.11M total) on 2026-09-14.
Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Health Catalyst Strengthens Its Board with the Appointment of Tami Reller Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Utah - September 14, 2026 - Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence
Recent HCAT coverage spans financial news, corporate actions and insider activity.
In the last 30 days, HCAT insiders filed 1 SEC Form 4 transaction — 1 purchase ($105K) and no sales. The most active reporter was Kohl Simeon, Chief Executive Officer, with 1 filing.
Leadership change at Health Catalyst could affect strategic direction but no immediate catalyst for price movement.
Insider buying by the CEO signals confidence but the transaction size is modest.
Board strengthening may support strategic execution and could be viewed positively by investors.
Leadership transition may influence strategic direction and operational performance.
Leadership transition may affect strategic direction and execution but short‑term price impact is likely limited.
AlphAI scores every news story that mentions HCAT with an AI model for sentiment and relevance, and aggregates insider trades from Health Catalyst, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
STAAR Surgical appointed David Bailey, former CEO, as Chief Commercial Officer to lead EVO ICL business. Bailey previously grew international revenue to 74% and ICL revenue to $32 million. He will focus on expanding in Asia, South America, and Africa.
2 min readKohl Simeon (Chief Executive Officer) purchased 59,000 shares of Health Catalyst, Inc. (HCAT) at $1.79 ($0.11M total) on 2026-09-14.
1 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Health Catalyst Strengthens Its Board with the Appointment of Tami Reller Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Utah - September 14, 2026 - Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence
1 min readHealth Catalyst appointed Simeon Kohl as CEO and President, effective September 14, 2026. Kohl succeeds Ben Albert, who transitions to Chief Business Officer. Kohl previously led Performant Healthcare's sale for $670 million. Health Catalyst cited Kohl's operational leadership and shareholder value creation. The company focuses on healthcare intelligence technology, with $2.8 billion in documented outcomes.
2 min readHealth Catalyst appointed Simeon Kohl as CEO and President, effective September 14, 2026. Ben Albert, the outgoing CEO, will become Chief Business Officer. Kohl previously led Performant Healthcare's sale for $670 million. Albert's tenure saw the divestiture of Vitalware, reducing $160 million in debt. Health Catalyst specializes in healthcare intelligence technology.
2 min readHealth Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President Kohl brings public-company leadership and a record of successful transformation; Ben Albert to continue as Chief Business Officer SALT LAKE CITY, Utah - September 8, 2026 - Health Catalyst,
1 min readHealth Catalyst (HCAT) CFO Jason Alger sold 17,973 shares at $1.7036 each to cover taxes on vesting RSUs, leaving him with 704,867 shares. The sale was mandated, not discretionary, under the company's equity plans.
1 min readHealth Catalyst director Julie Larson-Green received 9,766 restricted stock units (RSUs) under the company’s 2019 Stock Option and Incentive Plan. The RSUs vested immediately, increasing her holdings to 185,101 shares. The award was granted at no cash price, and no Rule 10b5-1 trading plan was reported.
1 min readAnalysts downgraded five companies: Teradyne (TER) to Neutral with a $420 target, Ternium (TX) to Hold with a $55 target, Health Catalyst (HCAT) to Hold with a $1.8 target, DoubleVerify (DV) to Neutral with a $13.6 target, and Limbach (LMB) to Underweight with a $50 target. Stocks closed at $383.15, $54.21, $1.63, $13.31, and $42.75 respectively.
1 min readBloomberg reported Anthropic’s preliminary Q2 revenue exceeded $11.5B, and CNBC said software firms face pressure that AI coding tools could reduce software spending. Shares of Health Catalyst (HCAT), GitLab (GTLB), Elastic (ESTC) and Marqeta (MQ) fell in afternoon trading. Health Catalyst guided Q3 revenue to $55.5M and cut 2026 revenue to $247.5M midpoint.
7 min read
